DaVita, Inc. (NYSE:DVA)

CAPS Rating: 3 out of 5

The Company is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease.

Recs

0
Player Avatar dvlchek (< 20) Submitted: 1/23/2009 6:35:21 PM : Outperform Start Price: $47.18 DVA Score: +12.47

This company's product is absolutely unrelated to any other aspect of the economy. All dialysis patients need and will receive dialysis, regardless of economics. The government pays the bills and will continue to do so. Costs are completely predictable and the company has managed them skillfully over the past eight years.

The company can predict revenue, cost, and earnings, with almost 100% accuracy, well into the future.

This is a no-brainer.

Featured Broker Partners


Advertisement